MDB Capital Posts Wider Q2 Loss as eXoZymes Stake Deteriorates
MDBH sits 23% above its 52-week low of $2.45 on elevated volume (2.8× avg).
Summary
MDB Capital's Q2 loss widened to $9.3M as its eXoZymes investment was impaired and cash declined. The eXoZymes stake has since fallen further, signaling more losses ahead.
Key Events · Earnings and Guidance · MDBH
-
Q2 Net Loss Widens
Net loss attributable to MDB Capital Holdings was $9.3M in Q2 2026, up from $8.2M in Q2 2025. Six-month loss was $16.1M vs $14.8M a year earlier.
-
eXoZymes Stake Impaired
The company recorded a $641K impairment on its equity method investment in eXoZymes, reducing the carrying value to $33.1M as of June 30, 2026.
-
Subsequent Decline in eXoZymes
eXoZymes shares fell to $5.76 by August 12, 2026, implying a further $11.3M decline in the fair value of MDB's stake below the June 30 carrying value.
-
Cash Position Drops
Cash and cash equivalents fell to $9.6M at June 30, 2026, from $13.2M at December 31, 2025, reflecting continued operating losses.
Analysis · MDBH · Finance
MDB Capital Holdings reported a Q2 net loss of $9.3 million, up from $8.2 million a year earlier, driven by a $641K impairment on its eXoZymes equity stake and continued unrealized losses on investment securities. The company's cash position fell to $9.6 million from $13.2 million at year-end, while the subsequent decline in eXoZymes shares to $5.76 implies a further $11.3 million hit to the investment's fair value. This matters because the company's largest asset is its eXoZymes stake, and its continued decline is eroding book value and could pressure future capital needs.
At the time of this filing, MDBH was trading at $3.02 on NASDAQ in the Finance sector, with a market capitalization of approximately $31.5M. The 52-week trading range was $2.45 to $4.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.